Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633540 · ClinicalTrials.gov registry record · Phase 2
Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02633540 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT02633540, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The aim of this study is to define a new treatment technique for T1a larynx cancer that maintains excellent local control with less extensive radiation fields. It is thought that this will lead to patients having fewer changes to their voice and a higher quality of life after treatment when compared to the current standard treatment.
Interventions
- RADIATION IMRT Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633540
The ClinicalTrials.gov registry entry for NCT02633540 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMRT Radiation is the first listed.
NCT02633540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633540 about?
NCT02633540 is a clinical study titled "Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function". The aim of this study is to define a new treatment technique for T1a larynx cancer that maintains excellent local control with less extensive radiation fields. It is thought that this will lead to patients having fewer changes to their voice and a higher quality of life after treatment when compared...
What is the current status of trial NCT02633540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-11-16. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02633540?
The interventions under investigation include: IMRT Radiation (RADIATION).
Who is sponsoring clinical trial NCT02633540?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.